Adaptimmune Therapeutics plc (“Adaptimmune”) (NASDAQ: ADAP) presented initial data from the first two cohorts of its ongoing studies with its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE